Your session is about to expire
← Back to Search
IMGN151 for Ovarian Cancer
Study Summary
This trial tests a new drug to treat recurrent endometrial, ovarian, peritoneal, and fallopian tube cancers in adults.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious illnesses or active infections.I have had cancer other than my current one in the last 3 years.I have a serious heart condition.I have previously been treated with a drug targeting FRα.I am willing to provide a sample of my tumor for testing.I do not have severe numbness or pain in my hands or feet.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.I have had extensive radiation therapy affecting a large part of my bone marrow.I have recurrent endometrial cancer or a specific type of ovarian, peritoneal, or fallopian tube cancer.I have a history of multiple sclerosis, Lambert-Eaton syndrome, or similar conditions.I had major surgery over 4 weeks ago and have recovered from it.I have brain metastases that are either untreated or causing symptoms.I have been diagnosed with recurrent endometrial cancer or high-grade ovarian, peritoneal, or fallopian tube cancer.I have severe liver disease.I need to take supplements that contain folate.I am not pregnant or breastfeeding.My ovarian cancer is of a specific type (endometrioid, clear cell, mucinous, sarcomatous, or low-grade).I agree to use effective birth control during and for 3 months after my treatment.I have had lung inflammation or a specific lung disease without infection.My blood, liver, and kidney functions are all within normal ranges.I have recovered from side effects of previous treatments, except for hair loss.I have at least one tumor that can be measured with a scan.
- Group 1: IMGN151 Open Label
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary aims of this clinical assessment?
"This clinical trial will assess safety over a period of up to 1 year, and its secondary objectives include measuring Progression Free Survival, Area Under the Plasma Concentration-Versus Time Curve From Time of Dose Until Tlast (AUClast) of IMGN151, Total B5327A Antibody, Free DM51 and S-Methyl DM51 pharmacokinetic parameters. Additionally the study seeks to determine Duration of Response."
What is the proposed sample size for this clinical trial?
"Yes, according to clinicaltrials.gov, this research is currently in the process of recruiting 227 volunteers from a single medical centre. The study was first posted on December 6th 2022 and has since been updated with fresh data."
Has the Food and Drug Administration officially authorized unblinded use of IMGN151?
"Due to the limited clinical data supporting safety and efficacy, IMGN151 Open Label has been rated a 1 on our team's scale of risk."
Is this clinical experiment recruiting participants at present?
"Affirmative. Evidence on clinicaltrials.gov confirms that this medical experiment, initially posted on December 6th 2022, is actively searching for participants. Specifically, 227 patients need to be recruited from one site."
Share this study with friends
Copy Link
Messenger